Figure 9.

SKOV-3 cell viability (a) and relative caspase-3 activation (b) after transfection with non-specific (NS) siRNA or AKT siRNA delivered by the G₆ TEA-core dendrimer nanovectors (N/P = 5) alone or in combination with paclitaxel (100 nM). Non-treated cells and β-actin were used as respective controls. (c) Tumor volumes from SKOV-3 xenografted mice treated with non-specific (NS) siRNA (top panel, left) or AKT siRNA delivered by the G₆ TEA-core dendrimer nanovectors (N/P = 5) alone (top panel, right) or in combination with paclitaxel (100 nM, bottom panel). (d) Drastic reduction of AKT levels in tumor xenografts injected with AKT siRNA G₆ TEA-core dendriplexes (bottom, left), and the corresponding histological sample showing sign of necrosis (bottom, right), compared with xenografts treated with NS siRNA delivered with the same nanovectors showing no reduction of AKT levels (top, left) and no necrosis (top, right). (e) Tumor volume during combined treatment of AKT siRNA G₆ TEA-core dendriplexes/paclitaxel (filled hot pink circles) of SKOV-3 mice xenografts, compared with nanodelivered AKT siRNA (open hot pink circles) or paclitaxel alone (filled gray circles). Data for nanodelivered NS siRNA are shown for control (open gray circles). Adapted from [47], which is an open access article published under an ACS AuthorChoice License.